Amgen Shines In Dark Times, Stays Mum On Bone-Drug Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
After a strong third quarter, execs make analysts wait to hear marketing ideas for denosumab.
You may also be interested in...
GlaxoSmithKline Looks To Revamp U.S. Operations In Tough Environment
U.S. sales fell 13 percent in the third quarter due to generic competition and Avandia.
Medicare National Policy On ESAs In Renal Setting Opposed By Physicians, Patients And Amgen
They ask CMS, at the very least, to analyze claims data from the agency’s ESA monitoring policy before making any new coverage determinations.
Amgen’s Positive Denosumab Pivotal Trial Reduces Overhangs For Firm
Big biotech needs the potential $2.4 billion analysts estimate the bone-building drug could bring by 2016.